Bristol-Myers Squibb Company (BMY) Stock Price, News, Analysis

Technical Score (1D)

NEUTRAL

News Sentiment

MIXED

What’s happening to BMY today?

Contineum Therapeutics provided an update on its clinical development pipeline, highlighting progress on its PIPE-791 program for idiopathic pulmonary fibrosis. This advancement signals Contineum's transition towards becoming a clinical-stage entity with key programs advancing. Additionally, catalysts related to Contineum's collaboration with Johnson & Johnson (BMY) were discussed at the Leerink Global Healthcare Conference. Investors will be watching for further updates on the BMY collaboration and the progression of the PIPE-791 program in the coming trading days.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

Contineum Therapeutics provided an update on its clinical development pipeline at the Leerink Global Healthcare Conference. The company highlighted progress on its PIPE-791 program for idiopathic pulmonary fibrosis (IPF) and discussed catalysts related to its collaboration with Johnson & Johnson (BMY). This presentation signals Contineum's transition towards becoming a clinical-stage entity with key programs advancing.

What did this article say?

Bristol Myers Squibb CEO Christopher S. Boerner has been appointed to Colgate-Palmolive's Board of Directors. This move, coupled with Colgate-Palmolive's modest dividend increase, suggests a strategic shift towards integrating healthcare expertise into its governance and capital allocation. The addition of Boerner's leadership is expected to influence Colgate-Palmolive's long-term strategy and investment narrative.

What did this article say?

Immatics N.V. reported strong enrollment in its Phase 3 SUPRAME trial for anzu-cel, a melanoma therapy. The company's 2025 revenue saw a significant decrease due to a one-time non-cash item related to its deal with Bristol Myers Squibb (BMY). This collaboration is a key factor in the advancement of Immatics' clinical programs.

What did this article say?

ImmunityBio's (IBRX) valuation has significantly increased, driven by accelerating Anktiva prescriptions and expansion. The current market valuation implies a high degree of confidence in flawless commercialization, including reimbursement, manufacturing, and regulatory follow-through. This premium leaves limited room for execution missteps as the company focuses on sustaining U.S. momentum and pursuing international launches and label expansions.

What did this article say?

ImmunityBio has transitioned to a commercial-stage company, with its lead asset Anktiva driving revenue and future milestones. The company is focused on U.S. demand, international authorizations, and multiple label-expansion efforts, positioning 2026 as a critical year for execution and regulatory progress. Anktiva's development as an immuno-oncology platform with potential for broad application underpins the investment narrative.

What did this article say?

A new market research report forecasts the Opdualag market, encompassing nivolumab and related cancer immunotherapy products. Opportunities are identified in personalized treatments, biomarker-driven therapies, and expanding dual-checkpoint immunotherapies. The report analyzes epidemiology, pipeline developments, market insights, and forecasts through 2035, covering sales of inhibitors and monoclonal antibodies.

What did this article say?

Bristol-Myers Squibb (BMY) presents a compelling dividend yield of 4.15%, demonstrating a history of growth. This is underpinned by robust profitability, although investors should monitor its elevated payout ratio and debt levels.

What did this article say?

Piper Sandler analysts believe Bristol-Myers Squibb (BMY) has a clear strategy for growth following the patent expiry of its key drug, Eliquis. The firm suggests that BMY's pipeline and ongoing portfolio management are sufficient to navigate this significant event. Investors should monitor the company's execution on its strategic initiatives and the performance of its newer assets.

What did this article say?

UBS has increased its price target for Bristol Myers Squibb (BMY) to $70 from $65, maintaining a Buy rating. The firm highlights upcoming Phase III data for milvexian in stroke prevention and atrial fibrillation as a significant catalyst for 2026. Additionally, an experimental drug for a rare blood cancer showed improved survival in a late-stage trial, meeting its primary goal.

What did this article say?

Editas Medicine's fourth-quarter results surpassed expectations with a smaller loss and higher revenues, largely due to reduced operating expenses. Collaboration revenues, including those from Bristol Myers, saw a year-over-year decrease, attributed to milestone achievements in the previous period. The company is moving its EDIT-401 gene-editing candidate towards its initial human study in 2026.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

BMY·Bristol-Myers Squibb Company

What’s happening to BMY today?

Recent News Coverage

Recent News Coverage